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ABSTRACT
Introduction The immune system is implicated in the 
aetiology and progression of Parkinson’s disease (PD). 
Inflammation and immune activation occur both in the 
brain and in the periphery, and a proinflammatory cytokine 
profile is associated with more rapid clinical progression. 
Furthermore, the risk of developing PD is related to genetic 
variation in immune- related genes and reduced by the use of 
immunosuppressant medication. We are therefore conducting a 
‘proof of concept’ trial of azathioprine, an immunosuppressant 
medication, to investigate whether suppressing the peripheral 
immune system has a disease- modifying effect in PD.
Methods and analysis AZA- PD is a phase II randomised 
placebo- controlled double- blind trial in early PD. Sixty 
participants, with clinical markers indicating an elevated 
risk of disease progression and no inflammatory or immune 
comorbidity, will be treated (azathioprine:placebo, 1:1) for 
12 months, with a further 6- month follow- up. The primary 
outcome is the change in the Movement Disorder Society- 
Unified Parkinson’s Disease Rating Scale gait/axial score in 
the OFF state over the 12- month treatment period. Exploratory 
outcomes include additional measures of motor and cognitive 
function, non- motor symptoms and quality of life. In addition, 
peripheral and central immune markers will be investigated 
through analysis of blood, cerebrospinal fluid and PK-11195 
positron emission tomography imaging.
Ethics and dissemination The study was approved 
by the London- Westminster research ethics committee 
(reference 19/LO/1705) and has been accepted by the 
Medicines and Healthcare products Regulatory Agency 
(MHRA) for a clinical trials authorisation (reference CTA 
12854/0248/001–0001). In addition, approval has been 
granted from the Administration of Radioactive Substances 
Advisory Committee. The results of this trial will be 
disseminated through publication in scientific journals and 
presentation at national and international conferences, and 
a lay summary will be available on our website.
Trial registration numbers ISRCTN14616801 and 
EudraCT- 2018-003089-14.
INTRODUCTION
Parkinson’s disease (PD) is a common neuro-
degenerative disorder diagnosed clinically by 
key motor features. The core pathology in PD 
involves the loss of dopaminergic neurons 
in the substantia nigra (SN) with intracel-
lular accumulation of alpha- synuclein aggre-
gates (Lewy bodies). Dopamine replacement 
therapy can control some of the motor symp-
toms. However, other problems including 
impaired balance and cognitive dysfunction 
are due to more widespread neurodegener-
ative pathology and are consequently unre-
sponsive to dopaminergic therapies. These 
symptoms progress such that by 10 years from 
diagnosis, around two- thirds of patients have 
balance and walking difficulties, and around 
half have dementia,1 with a profound impact 
on quality of life2 3 and care requirements.4 
There are currently no treatments to alter 
disease course and prevent these devastating 
complications, hence there is an urgent need 
to find effective disease- modifying thera-
pies for PD. There is increasing evidence 
that the immune system plays an important 
role in driving neurodegeneration in PD, 
and we propose that targeting the immune 
Strengths and limitations of this study
 ► First clinical trial of a peripherally acting immuno-
suppressive drug in Parkinson’s disease (PD).
 ► Robust, randomised double- blind placebo- controlled 
design.
 ► Novel patient stratification approach with recruit-
ment of a more rapidly progressing subgroup to op-
timise chance of demonstrating clinical effect.
 ► Detailed exploratory measures examining peripher-
al and central immune profile in PD to demonstrate 
proof of mechanism.
 ► As a single centre ‘proof of concept’ trial, sample 
size is limited to 60 participants.
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system may be an effective strategy for slowing disease 
progression.
The link between genetic variation in immune path-
ways and risk of PD is well established. Risk of developing 
PD is associated with polymorphisms in the human leuco-
cyte antigen (HLA) region, which encodes proteins vital 
to antigen recognition and presentation.5 6 Large- scale 
analyses of Genome Wide Association Study data also 
implicate the immune system in PD, demonstrating heri-
tability enrichment for genes of the adaptive immune 
system, including those involved in lymphocyte regula-
tion and cytokine signalling pathways.7 8 Further evidence 
of an immune contribution to PD risk comes from epide-
miological studies: individuals who regularly take non- 
steroidal anti- inflammatory drugs have reduced risk of 
developing PD,9 10 as do those on immunosuppressive 
therapy.11 There is also evidence that immune activation 
impacts on disease progression rate. In a large incident 
PD cohort, a proinflammatory serum cytokine profile at 
baseline was associated with faster motor progression and 
impaired cognition over 36 months of follow- up.12
Activation of microglia, the inflammatory cells of the 
brain, has been clearly demonstrated in patients with PD 
both at postmortem13–16 and using [11C]-PK11195 posi-
tron emission tomography (PET) imaging in vivo.17–19 
These cells have a role in responding to tissue injury, 
regulating the cerebral microenvironment and antigen 
presentation.20 It is thought that this activation is driven 
by toxic misfolded or post- translationally modified forms 
of alpha- synuclein released by degenerating cells, leading 
to secretion of proinflammatory and neurotoxic mole-
cules, resulting in a cyclical process of cell damage.21
Abnormalities in the peripheral immune profile in PD 
are also well demonstrated and include alterations in both 
the innate and adaptive immune compartments. There is 
a shift towards ‘classical’ (inflammatory) monocytes with 
elevated expression of activation markers,22 particularly 
in patients at higher dementia risk.23 In the T lymphocyte 
compartment, several authors have reported bias towards 
proinflammatory CD4+ lymphocyte subsets and produc-
tion of proinflammatory cytokines.24–27 There may also be 
a reduction in the number and function of CD4+ T- reg-
ulatory (Treg) cells, whose role is to counter this proin-
flammatory response.24 26 In addition, changes in the CD8 
compartment have been reported, with increased expres-
sion of activation markers and reduced markers of age- 
related senescence.28
Importantly, T cells with specificity for epitopes of alpha- 
synuclein have been identified and reported to occur at 
higher frequency in PD than controls; furthermore, their 
frequency was closely associated with possession of known 
PD risk alleles at the HLA locus,29 thus suggesting that 
alpha- synuclein may drive a peripheral adaptive immune 
response as well as an innate response of microglia in 
the brain. Elevated levels of alpha- synuclein specific anti-
bodies are also present in the early stages of PD.30 Periph-
eral immune cells may contribute to brain inflammation 
and neurotoxicity by trafficking into the central nervous 
system in PD. CD4+ and CD8+ lymphocytes have been 
shown to be present in increased numbers in the SN at 
postmortem in patients with PD,16 25 as well as in ex vivo 
cerebrospinal fluid (CSF) samples.31 The precise mech-
anism by which peripheral immune cells drive neuronal 
damage in PD is still unclear, but it has recently been 
demonstrated that Th17 cells from patients with PD drive 
cell death in autologous induced pluripotent stem cell 
(iPSC) derived dopaminergic midbrain neurons.25
Immune manipulation in animal models of PD alters 
disease susceptibility and severity. Using an 1- methyl-4- p
henyl-1,2,3,6- tetrahydropyridine (MPTP) mouse model 
of PD, studies have demonstrated that a lack of CD4+ 
lymphocytes attenuates dopaminergic cell death,16 as does 
administration of Treg cells.32 In mice that overexpress 
Figure 1 Overview of trial timeline. CSF, cerebrospinal fluid; 
PET, positron emission tomography.
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Figure 2 AZA- PD eligibility criteria. MDS, Movement Disorder Society; NSAIDs, non- steroidal anti- inflammatory drugs; PD, 
Parkinson’s disease; UKPDS, United Kingdom Parkinson's disease society; ALT, alanine transaminase; TPMT, thiopurine 
methyltransferase; VZV, varicella zoster virus; EBV, Epstein- Barr virus
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alpha- synuclein, knockout of major histocompatability 
class II (MHC) class II prevents both microglial activation 
and dopaminergic neurodegeneration.33 Furthermore, 
ciclosporin, a widely used immunosuppressant, is effec-
tive in improving motor and cognitive deficits in multiple 
mouse models of PD.34
Although animal models of PD indicate that immu-
nomodulatory therapies may have efficacy in protecting 
against neurodegeneration, there is limited clinical trial 
data in PD to date. Phase II trials of minocycline and 
pioglitazone, agents that reduce microglial activation in 
the brain in animal models, have been negative.35–37 An 
early phase trial of sargramostim, a human recombinant 
granulocyte- macrophage colony- stimulating factor that 
promotes differentiation of proinflammatory T- effector 
cells into Treg cells has reported a modest improvement 
in an exploratory outcome of motor function over 8- week 
treatment.38
We propose that direct suppression of the peripheral 
immune system is an alternative, highly relevant thera-
peutic strategy that has not been tested in clinical trials 
to date. Azathioprine is an immunosuppressant drug 
widely used in clinical practice for a range of immune- 
related conditions. It is a purine analogue that inhibits 
nucleic acid synthesis, hence reducing proliferation of 
lymphocytes involved in targeting and amplification of 
the immune response. It affects both the cell- mediated 
and antibody- mediated responses through reducing T 
and B lymphocyte proliferation.39 It was selected over 
other immunosuppressants because of its established effi-
cacy in a range of clinical conditions, including central 
nervous system disorders such as multiple sclerosis,40 and 
its acceptable safety profile with recognised protocols 
for toxicity monitoring. Furthermore, it is generally well 




AZA- PD is a randomised, double- blind, placebo- controlled 
trial of azathioprine in early PD that aims to provide 
‘proof of concept’ that a peripherally acting immunosup-
pressive drug can slow clinical disease progression. The 
trial will investigate whether the drug has an effect on 
disease course over 12 months of treatment and whether 
this is maintained over 6 months of subsequent follow- up. 
Sixty participants will be recruited and randomised 1:1 to 
receive active treatment or placebo. Clinical assessments 
will be performed at baseline, 6 months, 12 months and 
18 months (6 months postcompletion of treatment), with 
rigorous safety monitoring. In addition, the trial aims 
to demonstrate ‘proof of mechanism’ by evaluating the 
impact of azathioprine on blood, CSF and neuroimaging 
parameters of immune activation in the trial population 
and determining the relationship between these parame-
ters and clinical measures of disease progression.
The trial timeline is summarised in figure 1 .
Although AZA- PD is open to recruitment, given the 
current COVID-19 pandemic, recruitment has not 
commenced due to safety concerns. The Trial Steering 
Figure 3 Treatment monitoring schedule.
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Committee (TSC) and Data and Safety Monitoring Board 
(DSMB) will decide on an appropriate date to begin 
recruitment in due course, and protocol amendments to 
maximise patient safety will be submitted to the appro-
priate bodies when the best course of action has been 
determined. Our current aim is to start recruitment in 
March 2021, closing to recruitment in March 2022, with 
last patient last visit in November 2023, although this 
may be subject to change depending on the COVID-19 
pandemic.
Patient and public involvement (PPI)
Patients with PD and their partners and carers who attend 
our research clinic at the John van Geest Centre for Brain 
Repair (VGB), University of Cambridge, gave input into 
the protocol design. A PPI advisory panel of four patients/
carers reviewed the protocol and provided specific feed-
back, leading to the addition of optional components. 
The PPI panel also reviewed our participant information 
sheet for clarity.
Participant identification
Participants will be recruited from a single site in 
Cambridge, UK. Potential participants will be identified 
from the PD Research clinic database at the VGB. These 
individuals have undergone detailed clinical pheno-
typing, and information on demographics, comorbidities 
and medication is available. They have consented to be 
contacted about other research studies. Potential partici-
pants will be preselected by cross- referencing existing data 
with the inclusion/exclusion criteria outlined in figure 2. 
A key component of this process involves the calculation 
of a prognostic risk score, based on a model we have 
previously developed and validated, using age, Movement 
Disorder Society- Unified Parkinson’s Disease Rating 
Scale (MDS- UPDRS) axial score and semantic fluency 
to estimate risk of a poor prognosis (dementia, postural 
instability or death) within 5 years.41 Only patients with a 
risk greater than 50%, based on prior assessment at the 
research clinic, will be invited to take part. Approximately 
40% of those on the database fall within this group. This 
strategy has been adopted to maximise the probability of 
demonstrating significant slowing of clinical progression 
with azathioprine treatment.
Potential participants will be sent a copy of the partic-
ipant information sheet and telephoned after 2 weeks to 
determine whether they are interested in participating. 
If so, they will attend a screening visit, where written 
informed consent will be obtained before confirming 
eligibility.
Eligibility criteria
A potential participant will be deemed eligible for 
recruitment into AZA- PD if they meet the inclusion and 
exclusion criteria listed in figure 2. A review of medical 
history and blood tests will be used to determine 
eligibility.
Outcome measures
The primary outcome measure is change in MDS- UPDRS 
gait/axial score in the OFF state over the 12- month treat-
ment period. This is a clinical measure that has been 
shown to be the most sensitive measure of motor progres-
sion in PD, is relatively resistant to dopaminergic therapy 
and has an important impact on quality of life.42 This 
score is a sum of the points from the following sections of 
MDS- UPDRS part III:
 ► 3.1 – speech.
 ► 3.2 – facial expression.
 ► 3.9 – rising from a chair.
 ► 3.10 – gait.
 ► 3.12 – postural stability.
 ► 3.13 – posture.
 ► 3.14 – body bradykinesia.
Other outcome measures are exploratory and include:
 ► Change in MDS- UPDRS gait/axial score in OFF state 
at 18 months.
 ► Change in total MDS- UPDRS in OFF state at 12 and 
18 months.
 ► Change in electromagnetic sensor (EMS) measure-
ments while performing MDS- UPDRS tremor and 
bradykinesia assessments at 12 and 18 months.
 ► Proportion of patients developing postural instability 
(Hoehn and Yahr stage 3 or greater) at 12 and 18 
months.
 ► Change in global cognition (Addenbrooke’s Cogni-
tive Examination- III (ACE- III))) at 12 and 18 months.
 ► Change in patient- reported outcome measure of 
quality of life (Parkinson’s Disease Questionnaire 39 
(PDQ-39)) at 12 and 18 months.
 ► Change in Non- Motor Symptom Scale (NMSS) at 12 
and 18 months.
 ► Change in dose of symptomatic dopaminergic therapy 
(Levodopa Equivalent Daily Dose (LEDD)) at 12 and 
18 months.
 ► The safety and tolerability of azathioprine assessed by 
the number of adverse events (AEs) recorded during 
the 12- month treatment period.
 ► Change in [11C]-PK11195 PET non- dissociable 
binding potential (BPND) in subcortical and cortical 
regions of interest at 12 months.
 ► Change in total lymphocyte count at 6, 12 and 18 
months.
 ► Change in serum immunoglobulin levels at 6, 12 and 
18 months.
 ► Change in levels of serum and CSF cytokine levels at 
12 and 18 months.
 ► Change in lymphocyte subsets in blood and CSF at 12 
and 18 months.
Sample size calculation
The treatment effect size is unknown and therefore 
cannot be used to inform sample size calculations. A 
sample size of 60 has been selected pragmatically based 
on feasibility of recruitment.
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However, longitudinal clinical data from the Incidence 
of Cognitive Impairment in Cohorts with Longitudinal 
Evaluation- PD (ICICLE- PD) cohort study provides some 
idea of an anticipated effect size for the primary outcome 
measure. ICICLE- PD patients were stratified by cytokine 
profile. Those with a ‘proinflammatory’ profile (n=32) 
had a more rapid symptom progression, with mean (SD) 
annualised change in MDS- UPDRS gait/axial score of 
1.95 (1.92). In the subgroup with an ‘anti- inflammatory’ 
cytokine profile (n=26), mean (SD) annualised change 
in MDS- UPDRS gait/axial score was 0.72 (1.40).12 The 
corresponding between- group difference of 1.2 points 
is equivalent to a standardised effect size (Cohen’s d) of 
0.73. The magnitude of this effect, which equates to a 4% 
change on the 28- point gait/axial MDS- UPDRS subscale, 
would be clinically significant. For comparison, the esti-
mated minimum clinically important change on the full 
132- point MDS- UPDRS motor scale is ≈2% (2.5 points).43 
Furthermore, the axial- gait items of the MDS- UPDRS are 
those with the greatest impact on quality of life.42
As this is an early- phase proof of concept trial, it is 
important to maximise the chances of continuing devel-
opment if the treatment is genuinely effective, and thus 
a significance level of 25% under a one- sided test will be 
used. If the treatment effect is a 2% change (0.37 stan-
dardised effect), the design has 78% power, and for a 4% 




Clinical measures assessing both motor and non- motor 
components of PD will be performed at baseline, 
midtreatment, end of treatment and after 6- month 
further follow- up (see table 1). Throughout the course of 
the trial, participants will continue to take their PD medi-
cation as prescribed by their treating physician, and dose 
adjustments are permitted. However, some assessments 
will be conducted ‘OFF’ medication.
The MDS- UPDRS is widely used to quantify PD severity 
and includes questionnaires assessing the non- motor 
and motor aspects of the disease, a motor examination 
performed by a clinician and an assessment of motor 
complications (dyskinesias and fluctuations).44 The 
MDS- UPDRS part III will be assessed in the OFF state, in 
the absence of regular dopaminergic medication, with 
participants being asked to not take their levodopa in 
the 8 hours prior to the assessment or their long- acting 
agents (eg, ropinirole, pramipexole and rasagiline) in the 
preceding 36 hours. The aim of this is to expose under-
lying disease severity and avoid confounding effects from 
variability in medication doses or timing. This examina-
tion will be filmed to enable subsequent rating by an 
independent assessor to check inter- rater reliability. Our 
primary outcome measure is derived from the MDS- 
UPDRS: the gait/axial subscore, as previously discussed. 
Two sections of the MDS- UPDRS part III (tremor and 
bradykinesia) will be repeated while the participant is 
wearing an EMS (Polhemus Inc) on the index finger and 
thumb, which will give an objective measure of the partic-
ipant’s movements. Motor stage will also be evaluated 
using the Hoehn and Yahr scale, a five- point scale used 
to capture the stages of progression of PD, with stage 3 
representing the development of postural instability.45
Cognition will be assessed using the ACE- III. This 
provides a global measure of cognition as well as subscores 
in five domains; attention, memory, fluency, language 
and visuospatial function.46 Other non- motor aspects of 
PD will be evaluated using the short form 15- item Geri-
atric Depression Scale, a questionnaire assessing depres-
sive symptoms filled in by the participant,47 and the PD 
NMSS, completed by the trial assessor.48 Finally, we will 
use the PDQ-39, a self- rated questionnaire measuring 
PD- related quality of life.49
Dopaminergic medication requirement will be moni-
tored throughout the trial and standardised by calculating 
LEDD, which allows quantification of different doses and 
types of Parkinson’s medication on a single scale.50
PK-11195 PET imaging
[11C]-PK11195 PET will be used to measure activated 
microglia in the brain.17 18 Scanning will be conducted 
at the Wolfson Brain Imaging Centre (WBIC) on a GE 
SIGNA PET/MRI scanner, with the radiotracer produced 
at the WBIC Radiopharmaceutical Chemistry labora-
tory. MRI will be used for colocalisation. Five hundred 
megabecquerel of the[11C]-PK11195 radiotracer will be 
injected via a peripheral venous cannula over 30 s, and 
PET emission data will be acquired for 75 min postinjec-
tion in 55 time frames. Following image reconstruction 
and attenuation correction, specific tracer binding will be 
analysed with the simplified reference tissue model51 to 
quantify binding potential relative to a non- displaceable 
compartment (BPND). The reference region will be esti-
mated with supervised cluster analysis for [11C]PK11195 
from existing scans in healthy controls acquired on the 
same scanner. BPND will be compared pretreatment and 
post- treatment using a region of interest approach.
Given that some participants may have difficulty toler-
ating prolonged PET imaging, this will be optional. It 
will be performed between screening and baseline and 
repeated within 3 months following the end of treatment.
Biosample collection and processing
Fourteen millilitres of blood will be collected in serum 
tubes at baseline, midtreatment, end- of- treatment and 
follow- up visits for analysis of inflammatory cytokines, 
C reactive protein and immunoglobulins. Tubes will be 
centrifuged at 2000 RPM (600G) for 15 min following 
15 min clotting time for extraction of serum. Aliquots will 
be stored at −80°C for subsequent batch analysis using 
ELISA and electrochemiluminescence assays.
At baseline, end of treatment and follow- up visits, an 
additional 27 mL of blood will be collected in lithium 
heparin tubes for separation of peripheral blood mono-
nuclear cells (PBMCs) for immunophenotyping. A 
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concurrent full blood count (FBC) will be performed 
from an EDTA sample (2.6 mL).
CSF will be collected via lumbar puncture before the 
baseline visit and at the treatment endpoint. This is an 
optional component of the study in order to ensure that 
its inclusion does not limit recruitment. CSF will be spun 
at 400G for 10 min for extraction of immune cells for 
contemporaneous immunophenotyping alongside PBMC 
analysis. Supernatants will be stored at −80°C for later 
batch analysis of relevant immune and protein markers. 
Immunophenotyping will be performed for subsets of 
T cells, B cells and monocytes using flow cytometry, run 
within 24 hours of sample collection.
Treatment allocation, blinding and safety monitoring
Participants will be randomised 1:1 to receive azathio-
prine or placebo using Sealed Envelope, an online rando-
misation system. Clinical assessors and participants will 
be blinded to treatment allocation. Balanced assignment 
of each treatment will be achieved using permuted block 
randomisation, which will be stratified for: age ≤71 versus 
>71, and MDS- UPDRS- III ≤30 versus >30.
Treatment will be commenced at a dose of 1 mg/kg, 
based on 25 mg tablets of IMP (azathioprine/placebo). 
In addition to the visits shown in figure 1, treatment 
monitoring visits will be conducted to screen for poten-
tial complications associated with azathioprine. These 
will include blood tests to screen for myelosuppression, 
liver or renal dysfunction, AEs reporting and assessment 
of treatment compliance (review of patient- completed 
dosing diary and counting of the investigational medic-
inal product (IMP) at regular intervals). Initially, moni-
toring visits will occur 2 weekly, and after 4 weeks, the 
azathioprine dose will be increased to 2 mg/kg (assuming 
blood tests and clinical assessments are satisfactory), the 
standard therapeutic dose used in clinical practice. There 
will be a matched doubling of the placebo dose to main-
tain blinding. Once the participant is stable on their dose, 
treatment monitoring will be carried out less frequently 
(see monitoring protocol, figure 3).
Given that azathioprine will produce changes in FBC 
parameters, the blinded trial team conducting patient 
assessments and laboratory analysis will not have access 
to monitoring blood results throughout the duration of 
the trial. The blood tests will be reviewed by a separate 
unblinded team of clinicians, who will make decisions 
on dose changes when necessary. If a dose reduction is 
required, the participant will have an additional three 
monitoring visits at 2- weekly intervals to ensure stability 
of blood tests. Dose reductions and, where necessary, 
withdrawal of treatment will be carried out based on 
predefined clinical and laboratory criteria to ensure 
the safety of participants, including the development of 
significant myelosuppression, intolerable gastrointestinal 
side effects and hypersensitivity reactions. Participants 
who have been withdrawn from treatment will be encour-
aged to continue to attend the remainder of the trial 
assessments.
To ensure blinding is maintained among clinical asses-
sors and participants, dose adjustments and treatment 
withdrawals will be also made for an equal number of 
participants in the placebo arm, with additional moni-
toring visits. Matched pairs of placebo and azathioprine- 
treated participants will be generated to facilitate this, 
and all dose adjustment decisions will be made by the 
unblinded team.
Emergency unblinding will be carried out in the event 
of a valid medical or safety reason, where the clinical care 
of the participant will be facilitated by the knowledge of 
whether they have been taking azathioprine, as decided 
by the treating clinician. It will be executed using Sealed 
Envelope, and where possible, the trial team will remain 
blinded.
Following the end of the trial, and for participants who 
withdraw early, we will offer continuing follow- up through 
our research clinic at the VGB.
Trial monitoring and oversight
Safety monitoring will be overseen by a DSMB who will 
have access to interim recruitment and safety data. The 
DSMB will report to the TSC should it become clear that 
one treatment allocation is either indicated or contraindi-
cated, or apparent that no clear outcome can be obtained 
from the trial. The TSC, who are independent from the 
sponsor, will provide overall supervision of the trial and 
ensure that it meets appropriate standards. These groups 
include clinicians with experience in PD or immuno-
suppression and independent statisticians, and the TSC 
includes a lay member.
AZA- PD is jointly sponsored by Cambridge University 
Hospitals Natioanl Health Service Foundation Trust and 
the University of Cambridge. The sponsor will review all 
trial documentation, including any proposed amend-
ments, prior to submission to the relevant regulatory 
bodies, which can only be completed once the sponsor 
has approved the changes. Changes will then be commu-
nicated to participants, the DMSB, TSC and trial registries.
Adherence to the protocol and regulatory requirements 
will be reviewed by a Clinical Trials Monitor, assigned by 
the sponsor. The first monitoring visit will occur within 10 
days of the first randomisation, with frequency thereafter 
determined by a risk assessment, which will be reviewed 
and adjusted as necessary throughout the course of the 
trial.
DATA ANALYSIS
Trial data will be transferred from paper case report forms 
(CRFs) to the electronic trial database, where it will be 
anonymised, but with preserved linkage records. Patient- 
identifiable data (PID) will be stored on a password- 
protected database within the Secure Data Hosting 
Service (SDHS) hosted by the University of Cambridge, 
with access granted only to relevant members of the trial 
team. PID will be kept for 5 years following the end of the 
trial, as per regulatory requirements. Participant consent 
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will be specifically sought for data/sample sharing with 
our collaborators and use of remaining biological samples 
in future ethically approved research.
Data will be analysed on an ‘intention to treat’ basis, 
with further ‘per protocol’ analysis in participants with at 
least 80% compliance with trial medication. All endpoints 
will be summarised and broken down by treatment group 
and time point, where relevant. Mean, median, SD 
and minimum/maximum will be used for continuous 
endpoints and frequency tables for categorical or binary 
endpoints. Equivalent box and whisker plots or stacked 
bar charts will be produced for continuous and categor-
ical endpoints, respectively.
The primary analysis will estimate the difference 
between treatment groups in terms of the primary 
endpoint. An analysis of covariance (ANCOVA) model 
will be fitted adjusting for baseline MDS- UPDRS gait/
axial score, gender, LEDD and age. Treatment effect 
estimates, SEs, CIs (95% and 40% levels) and one- 
sided p values will be provided. A one- sided p value less 
than 25% will be regarded as statistically significant. 
Similar comparative analyses will be produced for other 
time points of the MDS- UPDRS gait/axial score and 
exploratory endpoints, using ANCOVA for continuous 
endpoints or logistic regression for categorical or binary 
endpoints.
Longitudinal data will use a mixed effect model 
repeated measurements (MMRM) analysis to include 
an unstructured patient- level random effect for nominal 
visit, visit and visit–treatment interaction fixed effects at 
visits post- baseline, with adjustment for baseline covari-
ates. To assess the slope of change over time, the longi-
tudinal data will be analysed using a similar MMRM 
but with a fixed effect of time from randomisation as a 
continuous, rather than nominal covariate, with a treat-
ment–time interaction to compare treatment groups and 
patient- level random effect for slope, with adjustment for 
baseline covariates.
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